Prediction of Phase II clinical outcome for stand-alone medication with novel target in schizophrenia

Drug with New Target for Schizophrenia

Background

• • • Development of compound with new target for schizophrenia as stand-alone
    • Target was weakly affected by few antipsychotics
    • No PET tracer available for drug exposure in humans
    • Development for augmentation therapy?

Proposed Quantitative Systems Pharmacology Solution

• • • Implementation of new target process in basal ganglia
    • Use calibrated and well equilibrated existing model for PANSS
    • Simulation of full dose-response in PANSS Model as stand-alone or for augmentation therapy

Outcome: Liu (2014)

• • Calibrated QSP PANSS Total model suggested relatively modest effect as stand-alone
  • Dose-response was very dependent upon nature and dose of antipsyhotic co-med